Open AccessSAFETY AND IMMUNOGENICITY OF COLD-ADAPTED RECOMBINANT INFLUENZA VECTOR EXPRESSING ESAT-6 AND AG85А ANTIGENS OF M. TUBERCULOSIS
Author(s) -
Maria V. Sergeeva,
A. A. Pulkina,
K. A. Vasiliev,
Ekaterina A. Romanovskaya-Romanko,
Andrey Komissarov,
Oleg A. Kuchur,
Andrej Egorov,
Л. М. Цыбалова,
Marina Stukova
Publication year - 2017
Publication title -
voprosy virusologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.151
H-Index - 15
eISSN - 2411-2097
pISSN - 0507-4088
DOI - 10.18821/0507-4088-2017-62-6-266-272
Subject(s) - esat 6 , immunogenicity , recombinant dna , virology , antigen , tuberculosis vaccines , western blot , vector (molecular biology) , biology , virus , tuberculosis , influenza vaccine , mycobacterium tuberculosis , immunology , medicine , gene , genetics , pathology
Recombinant viral vectors represent one of the most promising platforms for creating a new generation of vaccines against tuberculosis. We constructed a vaccine candidate based on a cold-adapted influenza vector with a truncated NS1 protein containing an insert of tuberculosis ESAT-6 and Ag85A antigens. The recombinant virus possessed a cold-adapted and temperature-sensitive phenotype and was attenuated for mice when administered intranasally. Immunofluorescent staining and Western blot showed the expression of ESAT-6 protein in MDCK cells infected by recombinant virus. After intranasal administration to mice, the recombinant virus stimulated a specific anti-tuberculosis CD4 + Th1-type response with the formation of polyfunctional antigen-specific T cells.